false
English
Catalog
2024 World Conference on Lung Cancer (WCLC) - ePos ...
EP.11D.01 A Phase II Study of Cadonilimab Plus Che ...
EP.11D.01 A Phase II Study of Cadonilimab Plus Chemotherapy as First-Line Treatment for PD-L1-Negative Advanced Non-Small Cell Lung Cancer:LungCadX
Back to course
Pdf Summary
This phase II study, titled LungCadX, investigates the efficacy and safety of cadonilimab plus chemotherapy as a first-line treatment for patients with PD-L1-negative advanced non-small cell lung cancer (NSCLC). Cadonilimab is a bispecific antibody targeting PD-1 and CTLA-4 pathways, intended to enhance anti-tumor activity. The study enrolled 44 patients, administering cadonilimab with platinum-based chemotherapy (carboplatin combined with either paclitaxel or pemetrexed, depending on the NSCLC type) for up to four cycles. Post initial treatment, patients continued with cadonilimab monotherapy in squamous cases, and cadonilimab with pemetrexed in non-squamous cases.<br /><br />The primary endpoint focused on the 12-month progression-free survival (PFS) rate, assessed per RECIST 1.1. Secondary endpoints included objective response rate (ORR), overall survival (OS), duration of response (DoR), disease control rate (DCR), and safety assessments. The exploratory phase aimed to identify potential biomarkers from blood and tumor tissues.<br /><br />Initial results show promising clinical efficacy, with an investigator-assessed ORR of 66.7%, reaching 93.3% in squamous patients and 40.0% in non-squamous patients. The disease control rate was 100.0%. However, treatment-related adverse events (TRAEs) were noted in 61.4% of patients, with grade 3 adverse events in 34.1% of cases. Common TRAEs included leukopenia, neutropenia, anemia, and thrombocytopenia, but no treatment-related deaths were reported.<br /><br />The study concludes that cadonilimab plus chemotherapy demonstrates promising anti-tumor activity and manageable safety profiles, suggesting its potential as a treatment option for PD-L1-negative advanced NSCLC. Further analysis is ongoing to explore long-term outcomes and biomarker associations with treatment efficacy and patient prognosis.
Asset Subtitle
Li Wang
Meta Tag
Speaker
Li Wang
Topic
Metastatic Non-small Cell Lung Cancer – Immunotherapy
Keywords
LungCadX
cadonilimab
chemotherapy
PD-L1-negative
NSCLC
progression-free survival
objective response rate
treatment-related adverse events
biomarkers
anti-tumor activity
×
Please select your language
1
English
5
普通话
11
Dutch